China's NMPA has approved InnoCare's registrational Phase III trial of BCL2 inhibitor ICP-248 (Mesutoclax) combined with orelabrutinib for first-line CLL/SLL treatment.
NTRK gene fusions, though rare, represent a significant therapeutic target across multiple cancer types, with first-generation TRK inhibitors showing remarkable response rates and durability in clinical trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.